Cargando…
Assessment of Self-Administration of Romiplostim in Patients with Immune Thrombocytopenic Purpura after Receipt of Home Administration Training Materials: a Cross-Sectional Study
INTRODUCTION: Romiplostim is a subcutaneously administered thrombopoietin-receptor agonist approved in the European Union for self-administration (or administration by a caregiver) in selected adult patients with chronic primary immune thrombocytopenia refractory to other treatments. To mitigate the...
Autores principales: | Schipperus, Martin, Kaiafa, Georgia, Taylor, Louise, Wetten, Sally, Kreuzbauer, Georg, Boshier, Andy, Seesaghur, Anouchka |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373377/ https://www.ncbi.nlm.nih.gov/pubmed/30232740 http://dx.doi.org/10.1007/s40264-018-0723-6 |
Ejemplares similares
-
Primary immune thrombocytopenia (ITP) treated with romiplostim in routine clinical practice: retrospective study from the United Kingdom ITP Registry
por: Doobaree, Indraraj Umesh, et al.
Publicado: (2019) -
Cost-effectiveness of adding rituximab to splenectomy and romiplostim for treating steroid-resistant idiopathic thrombocytopenic purpura in adults
por: Kikuchi, Kayoko, et al.
Publicado: (2015) -
Romiplostim for Primary Immune Thrombocytopenia in Routine Clinical Practice: Results from a Multicentre Observational Study in Germany
por: Reiser, Marcel, et al.
Publicado: (2021) -
Safe and Effective Administration of Caplacizumab in COVID-19-Associated Thrombotic Thrombocytopenic Purpura
por: Bruzzese, Antonella, et al.
Publicado: (2023) -
Reduced corticosteroid use in adult patients with primary immune thrombocytopenia receiving romiplostim
por: Michel, Marc, et al.
Publicado: (2011)